{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:42:07Z","timestamp":1789425727486,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81601731"],"award-info":[{"award-number":["81601731"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s12072-017-9805-2","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T03:46:56Z","timestamp":1498103216000},"page":"374-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Current progress in host innate and adaptive immunity against hepatitis C virus infection"],"prefix":"10.1007","volume":"11","author":[{"given":"Jijing","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"9805_CR1","doi-asserted-by":"crossref","unstructured":"Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124\u20131135","DOI":"10.1016\/S0140-6736(14)62401-6"},{"key":"9805_CR2","doi-asserted-by":"crossref","unstructured":"Rehermann B. HCV in 2015: advances in hepatitis C research and treatment. Nat Rev Gastroenterol Hepatol 2016;13:70\u201372","DOI":"10.1038\/nrgastro.2015.227"},{"key":"9805_CR3","doi-asserted-by":"crossref","unstructured":"Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004;127:S294\u2013S302","DOI":"10.1053\/j.gastro.2004.09.044"},{"key":"9805_CR4","doi-asserted-by":"crossref","unstructured":"Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359\u2013362","DOI":"10.1126\/science.2523562"},{"key":"9805_CR5","doi-asserted-by":"crossref","unstructured":"Khan AG, Whidby J, Miller MT, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014;509:381\u2013384","DOI":"10.1038\/nature13117"},{"key":"9805_CR6","doi-asserted-by":"crossref","unstructured":"Yang Z, Wang X, Chi X, et al. Neglected but important role of apolipoprotein E exchange in hepatitis C virus infection. J Virol 2016;90:9632\u20139643","DOI":"10.1128\/JVI.01353-16"},{"key":"9805_CR7","doi-asserted-by":"crossref","unstructured":"Fauvelle C, Felmlee DJ, Crochet E, et al. Apolipoprotein E mediates evasion from hepatitis C virus neutralizing antibodies. Gastroenterology 2016;150:206\u2013217","DOI":"10.1053\/j.gastro.2015.09.014"},{"key":"9805_CR8","doi-asserted-by":"crossref","unstructured":"Hiet MS, Bauhofer O, Zayas M, et al. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. J Hepatol 2015;63:829\u2013837","DOI":"10.1016\/j.jhep.2015.04.015"},{"key":"9805_CR9","doi-asserted-by":"crossref","unstructured":"Shata MT, Anthony DD, Carlson NL, et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepatol 2002;9(6):400\u2013410","DOI":"10.1046\/j.1365-2893.2002.00373.x"},{"key":"9805_CR10","doi-asserted-by":"crossref","unstructured":"Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191(9):1499\u20131512","DOI":"10.1084\/jem.191.9.1499"},{"key":"9805_CR11","doi-asserted-by":"crossref","unstructured":"Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 2016;16:509\u2013523","DOI":"10.1038\/nri.2016.69"},{"key":"9805_CR12","doi-asserted-by":"crossref","unstructured":"Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis 2013;207(Suppl 1):S7\u2013S12","DOI":"10.1093\/infdis\/jis762"},{"key":"9805_CR13","doi-asserted-by":"crossref","unstructured":"Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6(5):578\u2013582","DOI":"10.1038\/75063"},{"key":"9805_CR14","doi-asserted-by":"crossref","unstructured":"Veerapu NS, Raghuraman S, Liang TJ, et al. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 2011;140(2):676\u2013685","DOI":"10.1053\/j.gastro.2010.10.048"},{"key":"9805_CR15","doi-asserted-by":"crossref","unstructured":"Penna A, Pilli M, Zerbini A, et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007;45(3):588\u2013601","DOI":"10.1002\/hep.21541"},{"key":"9805_CR16","doi-asserted-by":"crossref","unstructured":"Abdel-hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol 2014;5:274","DOI":"10.3389\/fimmu.2014.00274"},{"key":"9805_CR17","doi-asserted-by":"crossref","unstructured":"Wiegand J, J\u00e4ckel E, Cornberg M, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004;40(1):98\u2013107","DOI":"10.1002\/hep.20291"},{"key":"9805_CR18","doi-asserted-by":"crossref","unstructured":"Zibert A, Meisel H, Kraas W, et al. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997;25(5):1245\u20131249","DOI":"10.1002\/hep.510250530"},{"key":"9805_CR19","doi-asserted-by":"crossref","unstructured":"Swann RE, Mandalou P, Robinson MW, et al. Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection. J Viral Hepatol 2016;23:873\u2013880","DOI":"10.1111\/jvh.12568"},{"key":"9805_CR20","doi-asserted-by":"crossref","unstructured":"Ahlenstiel G, Martin MP, Gao X, et al. Distinct KIR\/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 2008;118:1017\u20131026","DOI":"10.1172\/JCI32400"},{"key":"9805_CR21","doi-asserted-by":"crossref","unstructured":"Matsuura K, Tanaka Y. Host genetic variants influencing the clinical course of hepatitis C virus infection. J Med Virol 2016;88:185\u2013195","DOI":"10.1002\/jmv.24334"},{"key":"9805_CR22","doi-asserted-by":"crossref","unstructured":"Wandrer F, Falk CS, John K, et al. Interferon-mediated cytokine induction determines sustained virus control in chronic hepatitis C virus infection. J Infect Dis 2016;213:746\u2013754","DOI":"10.1093\/infdis\/jiv505"},{"key":"9805_CR23","doi-asserted-by":"crossref","unstructured":"Lau DT, Negash A, Chen J, et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2013;144(2):402\u2013413","DOI":"10.1053\/j.gastro.2012.10.044"},{"key":"9805_CR24","doi-asserted-by":"crossref","unstructured":"Miyagi T, Takehara T, Nishio K, et al. Altered interferon-alpha signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol 2010;53:424\u2013430","DOI":"10.1016\/j.jhep.2010.03.018"},{"key":"9805_CR25","doi-asserted-by":"crossref","unstructured":"Mondelli MU. Direct-acting antivirals cure innate immunity in chronic hepatitis C. Gastroenterology 2015;149:25\u201328","DOI":"10.1053\/j.gastro.2015.05.026"},{"key":"9805_CR26","doi-asserted-by":"crossref","unstructured":"Yin W, Tong S, Zhang Q, et al. Functional dichotomy of V\u03b42 \u03b3\u03b4 T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-\u03b3 production. Sci Rep 2016;6:26296","DOI":"10.1038\/srep26296"},{"key":"9805_CR27","doi-asserted-by":"crossref","unstructured":"Barathan M, Mohamed R, Vadivelu J, et al. Peripheral loss of CD8(+)CD161(++)TCRV\u03b17.2(+) mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients. Eur J Clin Invest 2016;46:170\u2013180","DOI":"10.1111\/eci.12581"},{"key":"9805_CR28","doi-asserted-by":"crossref","unstructured":"Zhang Y, El-Far M, Dupuy FP, et al. HCV RNA activates APCs via TLR7\/TLR8 while virus selectively stimulates macrophages without inducing antiviral responses. Sci Rep 2016;6:29447","DOI":"10.1038\/srep29447"},{"key":"9805_CR29","doi-asserted-by":"crossref","unstructured":"Raghuraman S, Park H, Osburn WO, et al. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T cell exhaustion. J Infect Dis 2012;205:763\u2013771","DOI":"10.1093\/infdis\/jir835"},{"key":"9805_CR30","doi-asserted-by":"crossref","unstructured":"Claassen MA, Janssen HL, Boonstra A. Role of T cell immunity in hepatitis C virus infections. Curr Opin Virol 2013;3(4):461\u2013467","DOI":"10.1016\/j.coviro.2013.05.006"},{"key":"9805_CR31","doi-asserted-by":"crossref","unstructured":"Gupta PK, Godec J, Wolski D, et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog 2015;11:e1005177","DOI":"10.1371\/journal.ppat.1005177"},{"key":"9805_CR32","doi-asserted-by":"crossref","unstructured":"Hartling HJ, Ballegaard VC, Nielsen NS, et al. Immune regulation in chronic hepatitis C virus infection. Scand J Gastroenterol 2016;51:1387\u20131397","DOI":"10.3109\/00365521.2016.1170875"},{"key":"9805_CR33","doi-asserted-by":"crossref","unstructured":"Radziewicz H, Ibegbu CC, Fernandez ML, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81(6):2545\u20132553","DOI":"10.1128\/JVI.02021-06"},{"key":"9805_CR34","doi-asserted-by":"crossref","unstructured":"Burke Schinkel SC, Carrasco-Medina L, Cooper CL, et al. Generalized liver- and blood-derived CD8+ T-cell impairment in response to cytokines in chronic hepatitis C virus infection. PLoS One 2016;11:e0157055","DOI":"10.1371\/journal.pone.0157055"},{"key":"9805_CR35","doi-asserted-by":"crossref","unstructured":"Bhattarai N, McLinden JH, Xiang J, et al. Conserved motifs within hepatitis C virus envelope (E2) RNA and protein independently inhibit T cell activation. PLoS Pathog 2015;11:e1005183","DOI":"10.1371\/journal.ppat.1005183"},{"key":"9805_CR36","doi-asserted-by":"crossref","unstructured":"Chen JH, Perry CJ, Tsui YC, et al. Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat Med 2015;21:327\u2013334","DOI":"10.1038\/nm.3831"},{"key":"9805_CR37","doi-asserted-by":"crossref","unstructured":"Pelletier S, Bedard N, Said E, et al. Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C. J Virol 2013;87(12):6769\u20136781","DOI":"10.1128\/JVI.02445-12"},{"key":"9805_CR38","doi-asserted-by":"crossref","unstructured":"Zabaleta A, Riezu-Boj JI, Larrea E, et al. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. J Med Virol 2016;88(5):843\u2013851","DOI":"10.1002\/jmv.24399"},{"key":"9805_CR39","doi-asserted-by":"crossref","unstructured":"Liang CC, Liu CH, Lin YL, et al. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. J Med Virol 2011;83(7):1212\u20131220","DOI":"10.1002\/jmv.22096"},{"key":"9805_CR40","doi-asserted-by":"crossref","unstructured":"Rana D, Chawla YK, Duseja A, et al. Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment. Liver Int 2012;32(7):1128\u20131137","DOI":"10.1111\/j.1478-3231.2011.02754.x"},{"key":"9805_CR41","doi-asserted-by":"crossref","unstructured":"Rodrigue-Gervais IG, Rigsby H, Jouan L, et al. Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance. PLoS One 2014;9(7):e102605","DOI":"10.1371\/journal.pone.0102605"},{"key":"9805_CR42","doi-asserted-by":"crossref","unstructured":"Crosignani A, Riva A, Della BS. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol 2016;22(4):1393\u20131404","DOI":"10.3748\/wjg.v22.i4.1393"},{"key":"9805_CR43","doi-asserted-by":"crossref","unstructured":"Tu Z, Zhang P, Li H, et al. Cross-linking of CD81 by HCV-E2 protein inhibits human intrahepatic plasmacytoid dendritic cells response to CpG-ODN. Cell Immunol 2013;284(1\u20132):98\u2013103","DOI":"10.1016\/j.cellimm.2013.07.012"},{"key":"9805_CR44","doi-asserted-by":"crossref","unstructured":"Sachdeva M, Chawla YK, Arora SK. Dendritic cells: the warriors upfront-turned defunct in chronic hepatitis C infection. World J Hepatol 2015;7(19):2202\u20132208","DOI":"10.4254\/wjh.v7.i19.2202"},{"key":"9805_CR45","doi-asserted-by":"crossref","unstructured":"Losikoff PT, Self AA, Gregory SH. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 2012;3(7):610\u2013620","DOI":"10.4161\/viru.21823"},{"key":"9805_CR46","doi-asserted-by":"crossref","unstructured":"Rodrigue-Gervais IG, Rigsby H, Jouan L, et al. Dendritic cell inhibition is connected to exhaustion of CD8+ T cell polyfunctionality during chronic hepatitis C virus infection. J Immunol 2010;184(6):3134\u20133144","DOI":"10.4049\/jimmunol.0902522"},{"key":"9805_CR47","doi-asserted-by":"crossref","unstructured":"Ryan EJ, Stevenson NJ, Hegarty JE, et al. Chronic hepatitis C infection blocks the ability of dendritic cells to secrete IFN-alpha and stimulate T-cell proliferation. J Viral Hepatol 2011;18(12):840\u2013851","DOI":"10.1111\/j.1365-2893.2010.01384.x"},{"key":"9805_CR48","doi-asserted-by":"crossref","unstructured":"Zhao L, Tyrrell DL. Myeloid dendritic cells can kill T cells during chronic hepatitis C virus infection. Viral Immunol 2013;26(1):25\u201339","DOI":"10.1089\/vim.2012.0058"},{"key":"9805_CR49","doi-asserted-by":"crossref","unstructured":"Zeng QL, Yang B, Sun HQ, et al. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR \u03b6 chain expression on CD8+ T cells in chronic hepatitis C patients. Mol Cells 2014;37(1):66\u201373","DOI":"10.14348\/molcells.2014.2282"},{"key":"9805_CR50","doi-asserted-by":"crossref","unstructured":"Ren JP, Zhao J, Dai J, et al. Hepatitis C virus-induced myeloid-derived suppressor cells regulate T cell differentiation and function via the STAT3 pathway. Immunology 2016;148:377\u2013386","DOI":"10.1111\/imm.12616"},{"key":"9805_CR51","doi-asserted-by":"crossref","unstructured":"Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302(5645):659\u2013662","DOI":"10.1126\/science.1088774"},{"key":"9805_CR52","doi-asserted-by":"crossref","unstructured":"Raziorrouh B, Ulsenheimer A, Schraut W, et al. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology 2011;141(4):1422\u20131431","DOI":"10.1053\/j.gastro.2011.07.004"},{"key":"9805_CR53","doi-asserted-by":"crossref","unstructured":"Kared H, Fabre T, Bedard N, et al. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 2013;9:e1003422","DOI":"10.1371\/journal.ppat.1003422"},{"key":"9805_CR54","doi-asserted-by":"crossref","unstructured":"Mele D, Mantovani S, Oliviero B, et al. Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. Antiviral Res 2017;137:108\u2013111","DOI":"10.1016\/j.antiviral.2016.11.013"},{"key":"9805_CR55","doi-asserted-by":"crossref","unstructured":"Barnes E, Gelderblom HC, Humphreys I, et al. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis 2009;199(6):819\u2013828","DOI":"10.1086\/597072"},{"key":"9805_CR56","doi-asserted-by":"crossref","unstructured":"Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med 2006;45:183\u2013191","DOI":"10.2169\/internalmedicine.45.1530"},{"key":"9805_CR57","doi-asserted-by":"crossref","unstructured":"Chang Q, Wang YK, Zhao Q, et al. Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. J Gastroenterol Hepatol 2012;27:273\u2013278","DOI":"10.1111\/j.1440-1746.2011.06782.x"},{"key":"9805_CR58","doi-asserted-by":"crossref","unstructured":"Neuman MG, Sha K, Esquerra R, et al. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008;53:1468\u20131487","DOI":"10.1007\/s10620-007-0047-3"},{"key":"9805_CR59","doi-asserted-by":"crossref","unstructured":"Pembroke T, Christian A, Jones E, et al. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in vivo resistance to interferon \u03b1 treatment. Gut 2014;63(3):515\u2013524","DOI":"10.1136\/gutjnl-2013-304472"},{"key":"9805_CR60","doi-asserted-by":"crossref","unstructured":"Kang W, Shin EC. Clinical implications of chemokines in acute and chronic hepatitis C virus infection. Yonsei Med J 2011;52:871\u2013878","DOI":"10.3349\/ymj.2011.52.6.871"},{"key":"9805_CR61","doi-asserted-by":"crossref","unstructured":"Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 2015;12:387\u2013400","DOI":"10.1038\/nrgastro.2015.94"},{"key":"9805_CR62","doi-asserted-by":"crossref","unstructured":"Ren JP, Ying RS, Cheng YQ, et al. HCV-induced miR146a controls SOCS1\/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development. J Viral Hepatol 2016;23:755\u2013766","DOI":"10.1111\/jvh.12537"},{"key":"9805_CR63","doi-asserted-by":"crossref","unstructured":"Veerapu NS, Park SH, Tully DC, et al. Trace amounts of sporadically reappearing HCV RNA can cause infection. J Clin Invest 2014;124(8):3469\u20133478","DOI":"10.1172\/JCI73104"},{"key":"9805_CR64","doi-asserted-by":"crossref","unstructured":"Dessouki O, Kamiya Y, Nagahama H, et al. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: reversion by anti-viral treatment. Biochem Biophys Res Commun 2010;393(2):331\u2013337","DOI":"10.1016\/j.bbrc.2010.02.008"},{"key":"9805_CR65","doi-asserted-by":"crossref","unstructured":"Ahlenstiel G, Edlich B, Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011;141(4):1231\u20131239","DOI":"10.1053\/j.gastro.2011.06.069"},{"key":"9805_CR66","doi-asserted-by":"crossref","unstructured":"Larrubia JR, Moreno-Cubero E, Miquel J, et al. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol 2015;21:3480\u20133491","DOI":"10.3748\/wjg.v21.i12.3480"},{"key":"9805_CR67","doi-asserted-by":"crossref","unstructured":"Zhang C, Hua R, Cui Y, et al. Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance. PLoS One 2017;12(2):e0171217","DOI":"10.1371\/journal.pone.0171217"},{"key":"9805_CR68","doi-asserted-by":"crossref","unstructured":"Serti E, Chepa-Lotrea X, Kim YJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015;149:190\u2013200.e2","DOI":"10.1053\/j.gastro.2015.03.004"},{"key":"9805_CR69","doi-asserted-by":"crossref","unstructured":"Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014;124:3352\u20133363","DOI":"10.1172\/JCI75938"},{"key":"9805_CR70","doi-asserted-by":"crossref","unstructured":"Martin B, Hennecke N, Lohmann V, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014;61:538\u2013543","DOI":"10.1016\/j.jhep.2014.05.043"},{"key":"9805_CR71","doi-asserted-by":"crossref","unstructured":"Burchill MA, Golden-Mason L, Wind-Rotolo M, et al. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals. J Viral Hepatol 2015;22(12):983\u2013991","DOI":"10.1111\/jvh.12465"},{"key":"9805_CR72","doi-asserted-by":"crossref","unstructured":"Hofmann M, Thimme R. MAIT be different-persisting dysfunction after DAA-mediated clearance of chronic hepatitis C virus infection. Eur J Immunol 2016;46(9):2099\u20132102","DOI":"10.1002\/eji.201646581"},{"key":"9805_CR73","doi-asserted-by":"crossref","unstructured":"Hengst J, Falk CS, Schlaphoff V, et al. DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis 2016;214(12):1965\u20131974","DOI":"10.1093\/infdis\/jiw457"},{"key":"9805_CR74","doi-asserted-by":"crossref","unstructured":"Callendret B, Eccleston HB, Satterfield W, et al. Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral. Hepatology 2016;63:1442\u20131454","DOI":"10.1002\/hep.28309"},{"key":"9805_CR75","doi-asserted-by":"publisher","unstructured":"Shrivastava S, Wilson E, Poonia B, et al. Augmentation of HCV specific immunity and sustained virological response (SVR). J Viral Hepatol 2017. doi:\n                        10.1111\/jvh.12702","DOI":"10.1111\/jvh.12702"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-017-9805-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-017-9805-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-017-9805-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T10:10:05Z","timestamp":1498731005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-017-9805-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["9805"],"URL":"https:\/\/doi.org\/10.1007\/s12072-017-9805-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]}}}